Thirteen polyaminopolycarboxylic acid chelating agents were evaluated in vitro and in vivo as potential therapeutic agents for acute beryllium poisoning.
LIST OF TABLES
This study was undertaken to determine (a) whether reversal of the berylliuminduced inhibition of rat plasma alkaline phosphatase might serve as a reliable screening test to disclose compounds that might be useful in the treatment of acute beryllium intoxication and (b) to evaluate a group of polyaminopolycarboxylic acids for effectiveness in counteracting in vitro and in vivo the toxic manifestations of beryllium.
SECTION II METHODS AND MATERIALS

TEST MATERIALS
Beryllium sulfate tetrahydrate (BeSO4.4H20) was obtained from Fisher Scientific Company.
The in vitro results obtained with this source of beryllium were compared with those using a sample of the same BeSO4.4H 2 0 (C. P. Eimer & Amend) that was used in the studies of Lindenbaum et al (ref 3) .
No significant differences could be detected between these two beryllium sources with respect to their effect on alkaline phosphatase activity. Aurintricarboxylic acid (ATA) was obtained from Fisher Chemical Company (A546 Reagent Grade, ammonium salt). Salicylic acid (SA) was obtained from Matheson, Coleman & Bell (CB 748, as sodium salt).
The polyaminopolycarboxylic acids were obtained through the curtesy of Dr. Murray Weiner, Geigy Chemical Corporation, Ardsley, New York.
These compounds were available only in small amounts (2 to 5 g each).
These acids are coded as follows: 
Sprague-Dawley rats were used throughout the study. Female animals weighing approximately 250 g each were used as sources of blood in the in vitro portions of the study. Male rats exclusively were used for the in vivo portions of the study, to avoid complications that might result from interactions between strong chelating agents, inorganic ions, and endocrine functions.
TEST METHODS
Alkaline Phosphatase Determinations
The activity of plasma alkaline phosphatase was measured by the method of Bodansky This test system involved the incubation of 0.1 ml of plasma from freshly drawn cardiac blood with 1.0 ml of 0.025 M Veronal buffer (pH 8.9) containing 0.015 M sodium 8-glycerophosphate and water (or beryllium sulfate and test solutions) to make a final volume of 1.7 ml. After incubation at 380 C for 30 minutes, the reaction was stopped by the addition of 0.3 ml of 50% trichloroacetic acid. After centrifugation, the inorganic phosphate was measured by the method of Fiske and SubbaRow (ref 6).
The inhibition of alkaline phosphatase by beryllium was studied at beryllium concentrations that provided approximately 35 percent and 65 percent inhibition. Reversal of the beryllium-induced inhibition was determined by addition to the in vitro system of a tenfold and twentyfold molar excess of the test compound relative to beryllium. From the measured activity of the enzyme in the presence of both beryllium and the test compound, the percent reversal of the beryllium inhibition was calculated from the formula:
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observed inhibition I00 1 -% ihibition of Be Controld Thus, at a beryllium concentration of 4 x 10-6 M, which produced a 37 percent inhibition of alkaline phosphatase activity, the test chemicals were added to the test system at 4 x 10-5 M and 8 x 10-5 M, a tenfold and twentyfold molar excess, respectively. At beryllium concentrations of 10-5 M, which produced a 65 percent inhibition of enzyme activity, test compounds were evaluated at 10-4 M and at 2 x 10-4 M (ref 2).
In vivo Toxicity
Animals were individually caged on wood shavings with a standard laboratory ration and water available ad libitum. The animal room was maintained at 230 C and a relative humidity of 50% to 60%.
Animals were fasted for 16 hours before administration of the chemicals.
Beryllium sulfate was administered intravenously as a sterile aqueous solution in the tail vein. Injection time in all cases was approximately 15 seconds.
Either aqueous solutions of polyaminopolycarboxylic acids or their solutions after neutralization with equimolar solution of calcium-sodium hydroxide were administered by intraperitoneal injection within 5 minutes after injection of the beryllium sulfate solution.
Two test compounds were administered orally by stomach tube in addition to the intraperitoneal injection. The curve, however, is quite steep, which indicates that relatively small changes in concentration can cause large differences in response.
In the test system reported here, a concentration of 3.5 x 10-6 M of Be++ appeared to be the 35-percent inhibition concentration while 1.0 x 10-5 M was the 65% inhibition value.
A number of the polyaminopolycarboxylic acids were themselves inhibitors of rat plasma alkaline phosphatase.
EDTA, DAEE TA, (DCMACH)ED TriA, PG(AEE) TA, TATEA HA, and TEPA HA all significantly inhibited alkaline phosphatase activity in the concentration range of interest (table II) .
The effects of the various chelating agents on beryllium-induced inhibition of alkaline phosphatase are presented in table 3 and summarized in table 4 . With the exception of ATA and SA none of the chelating agents was remarkable in its ability to reverse the inhibition by beryllium. DAEE TA, (AE)CHA TA, and TEPA HA were the superior agents in this test. Even in the absence of beryllium each of these agents at the molar concentrations required to provide a tenfold to twentyfold excess of beryllium inhibited the activity of alkaline phosphatase by ten to twenty percent (table II) . Since the observed inhibition of enzyme activity in the in vitro system might be an additive, combined inhibition effect of the test chemical and beryllium, it was possible that the in vivo activity of these compounds in reversing beryllium toxicity might be greater than the in vitro data indicated. Observed activity of alkaline phosphatase in fresh rat plasma 0.34 mg P/ml/hour
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Clinical Appearance
During injection the animals appeared unduly agitated, as evidenced by squealing and struggling. Some immediately went into deep coma-like depression, resting on side position, with intermittent respiratory arrest and spasmodic breathing. After 5 to 8 minutes, however, most of the animals exhibited normal behavior, although a few were slightly depressed. After 2 days post-treatment the survivors became acutely ill and were in deep depression. Food intake was practically nil. Most of the survivors showed yellowish discoloration of the ears, legs and tails, indicative of jaundice.
Gross Necropsy
Even at the lowest dose (0.35 mg Be++/kg) most of the animals exhibited a yellowish discoloration of the liver. In a number of cases, livers were swollen and spleens were enlarged.
At dosages of 0.51 mg Be++/kg and higher, the same pathologic alterations were noted although jaundice was more pronounced. In addition, there were petechial hemorrhages in various organs: lungs, thymus, intestines and lymph nodes.
In the (10.2 mg Be++/kg) and higher dose groups, additional necropsy findings included pronounced fluid accumulation in the chest cavity (hydrothorax).
LD 5 0 Calculations
The mortality data of rats receiving beryllium are plotted in figure 2 and summarized in The 48-hour LD 5 0 of beryllium was 246 mg/kg (1.5 to 4.6 mg/kg) while the 48-hour LD 9 5 was 14.5 mg/kg (6 to 36 mg/kg). Test compounds were evaluated at both the 48-hour LD 9 5 of beryllium and at the 0.7 mg/kg dose, reported by Lindenbaum which is, in these experiments, a 14-day LD 8 3 acute toxicity.
ACUTE TOXICITY OF POLYAMINOPOLYCARBOXYLIC ACIDS
The available amounts of test chemicals were quite limited (2 to 5 g each).
Hence, only a limited number of animals were used to determine the intraperitoneal toxicity of each compound. The results of these experiments are presented in table 7. From these data an estimate was made of the Maximum Tolerated Dose (MTD). In some cases inadequate amounts of the test chemical were available to use the MTD. In those cases doses approaching the maximum tolerated dose, commensurate with the available amount of chelating agent on hand, were administered.
In cases in which all of the rangefinding doses produced some pharmacological effects estimates of the MTD were made. Such estimates were based upon the doses causing mortality and/or other clinical symptoms and frequently represent 0.4 log interval of the lethal dose.
In practically all cases, the MTD's for the free acids and the sodium-calcium salts were equivalent.
THERAPEUTIC EFFECTS OF POLYAMINOCARBOXYLIC ACIDS IN BERYLLIUM POISONING
The mortality data presented in table 8 show that none of the compounds was remarkably effective in preventing the toxic effects of beryllium. ATA which reduced the toxicity of Be+t from 90% to 55% was the most effective; this effectiveness was achieved only by intraperitoneal administration of the ATA; oral administration of ATA was ineffective.. SA at 200 mg/kg, DET PA at 300 mg/kg, TATEA HA at 200 mg/kg, and TEPA HA at 400 mg/kg, when administered intraperitoneally, reduced the mortality of 0.71 mg/kg of Be++ from 90% to 70%. With the limited amount of test chemical and the limited number of animals per group, it could not be determined whether this reduction in mortality was significant.
None of the compounds was effective against 10 mg of Be t +/kg. Necropsy of all animals revealed the same gross pathological findings as the "untreated" beryllium control groups.
The results of this study indicate that the polyaminopolycarboxylic acids are rather ineffectual in preventing beryllium-induced mortality. Three compounds, (AE)CHA TA, TATEA HA, and TEPA HA, reduced mortality to about 70% as compared to 90% mortality with no chelating agent. With the exception of (AE)CHA TA in which 20 animals received 400 mg/kg, the reduction of mortality by 2 animals per dose group is of questionable significance. These findings are consistent with the hypothesis of Schubert (ref 10) that compounds, in order to be effective against beryllium, must possess an ortho hydroxy carboxyl structure. ATA and SA both have such structures, The hydroxy and glycol polyaminopolycarboxy acids were ineffective in this study. 14 days .4*.VI 04
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C' SECTION IV CONCLUSIONS None of the polyaminopolycarboxylic compounds were as effective as ATA in preventing the beryllium-induced mortality of male rats. The most effective compound, ATA, was active in both the in vitro system and the in vivo systems. The in vitro reversal of berylliumainduced inhibition of rat serum alkaline phosphatase appears to have merit as a preliminary exclusion screening test for compounds with potential in vivo activity; on the basis of this study, however, a compound which does not cause at least a 50% reversal of alkaline phosphatase inhibition will be of little value in preventing beryllium intoxication in rats.
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Qualified requesters may obtain copies of this report from DDC. Available, for sale to the public, from the Clearinghouse for Federal Scientific and Technical Information, CFSTI (formerly OTS), Sills Bldg, Springfield., Virginia 22151 Thirteen polyaminopolycarboxylic acid chelating agents were evaluated in vitro and in vivo as potential therapeutic agents for acute beryllium poisoning. In the in vitro test system the ability of the chelating agent to reverse beryllium induced inhibition of alkaline phosphate was measured. In the in vivo system, the chelating agent was evaluated by its ability to prevent mortality of rats that had received an acute lethal dose (LDs) of beryllium sulfate. None of the polyaminopolycarboxylic acids reversed completely the inhibition of alkaline phosphatase at either 35 percent or 65 percent levels of inhibition. All compounds were ineffective in overcoming the toxic dose of beryllium in rats.
